Company Analysis Stoke Therapeutics, Inc.
1. Summary
Advantages
- Price (11.59 $) is less than fair price (12.64 $)
- The stock's return over the last year (-16.44%) is higher than the sector average (-21.58%).
Disadvantages
- Dividends (0%) are below the sector average (0.5261%).
- Current debt level 0.8551% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-45.8%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Stoke Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 4% | -21.2% | -0.3% |
| 90 days | 80.2% | -21.7% | 10% |
| 1 year | -16.4% | -21.6% | 9.7% |
STOK vs Sector: Stoke Therapeutics, Inc. has outperformed the "Healthcare" sector by 5.15% over the past year.
STOK vs Market: Stoke Therapeutics, Inc. has significantly underperformed the market by -26.17% over the past year.
Slightly volatile price: STOK is more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: STOK with weekly volatility of -0.3161% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (11.59 $) is lower than the fair price (12.64 $).
Price not significantly lower than the fair price: The current price (11.59 $) is slightly lower than the fair price by 9.1%.
4.2. P/E
P/E vs Sector: The company's P/E (21.65) is lower than that of the sector as a whole (63.23).
P/E vs Market: The company's P/E (21.65) is lower than that of the market as a whole (89.86).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.6) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (2.6) is lower than that of the market as a whole (9.35).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (16.3) is lower than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (16.3) is higher than that of the market as a whole (10.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.64) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.64) is lower than that of the market as a whole (50.71).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 14.22% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (14.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-45.8%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-45.8%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-35.6%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-35.6%) is lower than that of the market as a whole (6.88%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-36.34%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-36.34%) is lower than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5261%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
